drugset

drugset / Trial / NCT00097903

Trial of Oral Karenitecin in Patients With Solid Tumors and Lung Cancer

NCT00097903 ↗

Phase 1 Completed 32 enrolled BioNumerik Pharmaceuticals, Inc. Crown Bioscience · collab

Non-randomizedFactorialOpen-labelTreatment

Summary

The purpose of this study is to determine the maximum safe dose of orally administered Karenitecin (BNP1350) in patients with solid tumors.

Timeline

Start: 2004-05
Primary completion: 2011-10
Completion: 2013-05

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cositecan	Small molecule	—	Intravenous

Indications